+高级检索
首页 > 优先出版
PDF HTML阅读 XML下载 导出引用 引用提醒
lncRNA 在肺动脉高压分子机制中的最新研究进展
作者:
作者单位:

1.昆明医科大学第二附属医院检验科;2.昆明医科大学第二附属医院呼吸与危重症医学科;3.昆明医科大学第一附属医院心血管内科

基金项目:

云南省科技厅-昆明医科大学应用基础研究联合专项基金面上项目（202101AY070001-130）；云南省心脑血管临床医学研究中心子课题项目（ZX2019-03-01）；昆明医科大学研究生创新基金（2024S311）；昆明医科大学研究生创新基金（2024S287）


Recent progress of research into the role of lncRNA in the molecular mechanism of pulmonary hypertension
Author:
Affiliation:

1.Department of Clinical Laboratory, the Second Affiliated Hospital of Kunming Medical University;2.Department of Respiratory and Critical Care Medicine, the Second Affiliated Hospital of Kunming Medical University;3.Department of Clinical Laboratory,the Second Affiliated Hospital of Kunming Medical University;4.Department of Cardiovascular Medicine,the First Affiliated Hospital of Kunming Medical University

Fund Project:

Yunnan Provincial Department of Science and Technology-Kunming Medical University Joint Special Fund for Applied Basic Research at the top level(202101AY070001-130)；Sub-topic project of Yunnan Provincial Cardiovascular and Cerebrovascular Clinical Medical Research Center (ZX2019-03-01);Graduate Student Innovation Fund of Kunming Medical University (2024S311);Graduate Student Innovation Fund of Kunming Medical University (2024S287)

  • 摘要
    • | |
  • 访问统计
    • |
  • 参考文献 [49]
    • | | | |
  • 文章评论
    摘要:

    肺动脉高压(pulmonary hypertension,PH)是一种致命性的疾病，其特征是肺血管结重构，最终导致右心衰竭和死亡。目前PH治疗并不理想，晚期PH患者的总生存率没有实质性改善。尽管目前在PH发病机制方面取得了部分进展，但仍需在分子水平上进行更多探索，以开发更有效的PH治疗方法。近年来研究表明长链非编码RNA(long non-coding RNA,lncRNA)在PH病理生理过程中发挥重要的调节功能，并成为潜在的疾病生物标志物和治疗靶点。本文就近年来lncRNA在PH中的分子机制进行综述。

    Abstract:

    Pulmonary hypertension (PH) is a fatal disease characterized by pulmonary vascular remodeling that ultimately leads to right heart failure and death. Current PH treatment is suboptimal, with no substantial improvement in the overall survival of patients with advanced PH. Despite the current partial progress has been made in the pathogenesis of PH, more exploration at the molecular level is needed to develop more effective treatments for PH. Recent researches have shown that long non-coding RNA (lncRNA) plays an important regulatory function in the pathophysiological process of PH, and has become a potential disease biomarker and therapeutic target. In this paper, we review the molecular mechanisms of lncRNA in PH in recent years.

    参考文献
    [1] HUMBERT M, KOVACS G, HOEPER M M, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension [J]. G Ital Cardiol. 2023, 24(4 Suppl 1): e1-e116.
    [2] DENG L, HAN X, WANG Z, et al. The landscape of noncoding RNA in pulmonary hypertension [J]. Biomolecules. 2022, 12(6): 796.
    [3] 王利然, 杨丽红, 宁文华, 等. 长链非编码RNA调控血管新生的研究进展 [J]. 中国比较医学杂志, 2021, 31(04): 143-149.WANG L R, YANG L H, NING W H, et al. Research progress of long non-coding RNA involvement in angiogenesis [ J]. Chin J Comp Med, 2021, 31(4): 143-149
    [4] 贡时雨, 范慧敏, 张旭敏, 等. LncRNA在心力衰竭预后判断和治疗中的潜力研究进展 [J]. 中国比较医学杂志, 2018, 28(02): 102-105.GONG S Y, FAN H M, ZHANG X M, et al. Research progress of LncRNA in prognosis and treatment of heart failure [ J]. Chin J Comp Med, 2018, 28(02): 102-105.
    [5] WANG E, WANG H, CHAKRABARTI S. Endothelial-to-mesenchymal transition: An underappreciated mediator of diabetic complications [J]. Front Endocrinol (Lausanne). 2023, 14: 1050540.
    [6] MONTEIRO J P, RODOR J, CAUDRILLIER A, et al. MIR503HG loss promotes endothelial-to-mesenchymal transition in vascular disease [J]. Circ Res. 2021, 128(8): 1173-1190.
    [7] CAO T, JIANG Y, LI D, et al. H19/TET1 axis promotes TGF-β signaling linked to endothelial-to-mesenchymal transition [J]. Faseb J. 2020, 34(6): 8625-8640.
    [8] THOMAS A A, BISWAS S, FENG B, et al. LncRNA H19 prevents endothelial-mesenchymal transition in diabetic retinopathy [J]. Diabetologia. 2019, 62(3): 517-530.
    [9] LI H, ZHAO Q, CHANG L, et al. LncRNA MALAT1 modulates ox-LDL induced EndMT through the Wnt/β-catenin signaling pathway [J]. Lipids Health Dis. 2019, 18(1): 62.
    [10] QIN Y, ZHU B, LI L, et al. Overexpressed lncRNA AC068039.4 contributes to proliferation and cell cycle progression of pulmonary artery smooth muscle cells via sponging miR-26a-5p/TRPC6 in hypoxic pulmonary arterial hypertension [J]. Shock. 2021, 55(2): 244-255.
    [11] HAO X, LI H, ZHANG P, et al. Down-regulation of lncRNA Gas5 promotes hypoxia-induced pulmonary arterial smooth muscle cell proliferation by regulating KCNK3 expression [J]. Eur J Pharmacol. 2020, 889: 173618.
    [12] WANG D, XU H, WU B, et al. Long non?coding RNA MALAT1 sponges miR?124?3p.1/KLF5 to promote pulmonary vascular remodeling and cell cycle progression of pulmonary artery hypertension [J]. Int J Mol Med. 2019, 44(3): 871-884.
    [13] WANG S, CAO W, GAO S, et al. TUG1 regulates pulmonary arterial smooth muscle cell proliferation in pulmonary arterial hypertension [J]. Can J Cardiol. 2019, 35(11): 1534-1545.
    [14] HAN Y, LIU Y, YANG C, et al. LncRNA CASC2 inhibits hypoxia-induced pulmonary artery smooth muscle cell proliferation and migration by regulating the miR-222/ING5 axis [J]. Cell Mol Biol Lett. 2020, 25: 21.
    [15] SONG R, LEI S, YANG S, et al. LncRNA PAXIP1-AS1 fosters the pathogenesis of pulmonary arterial hypertension via ETS1/WIPF1/RhoA axis [J]. J Cell Mol Med. 2021, 25(15): 7321-7334.
    [16] WANG S, ZHANG C, ZHANG X. Downregulation of long non?coding RNA ANRIL promotes proliferation and migration in hypoxic human pulmonary artery smooth muscle cells [J]. Mol med rep. 2020, 21(2): 589-596.
    [17] HE M, SHEN J, ZHANG C, et al. Long-chain non-coding RNA metastasis-related lung adenocarcinoma transcript 1 (MALAT1) promotes the proliferation and migration of human pulmonary artery smooth muscle cells (hPASMCs) by Regulating the microRNA-503 (miR-503)/toll-like receptor 4 (TLR4) signal axis [J]. Med Sci Monit. 2020, 26: e923123.
    [18] WANG H, QIN R, CHENG Y. LncRNA-Ang362 Promotes pulmonary arterial hypertension by regulating miR-221 and miR-222 [J]. Shock. 2020, 53(6): 723-729.
    [19] YANG L, LIANG H, SHEN L, et al. LncRNA Tug1 involves in the pulmonary vascular remodeling in mice with hypoxic pulmonary hypertension via the microRNA-374c-mediated Foxc1 [J]. Life Sci. 2019, 237: 116769.
    [20] LIU Y, HU R, ZHU J, et al. The lncRNA PAHRF functions as a competing endogenous RNA to regulate MST1 expression by sponging miR-23a-3p in pulmonary arterial hypertension [J]. Vasc Pharmacol. 2021, 139: 106886.
    [21] GONG J, CHEN Z, CHEN Y, et al. Long non-coding RNA CASC2 suppresses pulmonary artery smooth muscle cell proliferation and phenotypic switch in hypoxia-induced pulmonary hypertension [J]. Respir Res. 2019, 20(1): 53.
    [22] FENG X, WANG K, YANG T, et al. Overexpressed microRNA (miR)-382-3p promoted vascular remodeling via suppressing autophagy-related protein 7 (ATG7) in chronic thromboembolic pulmonary hypertension [J]. Curr Mol Med. Published online August 22, 2023.
    [23] FENG X, WANG K, YANG T, et al. LncRNA-GAS5/miR-382-3p axis inhibits pulmonary artery remodeling and promotes autophagy in chronic thromboembolic pulmonary hypertension [J]. Genes Genom. 2022, 44(4): 395-404.
    [24] LEISEGANG M S, FORK C, JOSIPOVIC I, et al. Long noncoding RNA MANTIS facilitates endothelial angiogenic function. Circulation [J]. 2017, 136(1): 65-79..
    [25] POYATOS P, GRATACóS M, SAMUEL K, et al. Oxidative stress and antioxidant therapy in pulmonary hypertension [J]. Antioxidants (Basel). 2023, 12(5): 1006.
    [26] LI W W, CAO A H, SUN F Y. LncRNA MIAT stimulates oxidative stress in the hypoxic pulmonary hypertension model by sponging miR-29a-5p and inhibiting Nrf2 pathway [J]. Eur Rev Med Pharmaco. 2020, 24(17): 9022-9029.
    [27] LIU J, ALI M K, MAO Y. Emerging role of long non-coding RNA MALAT1 related signaling pathways in the pathogenesis of lung disease [J]. Front Cell Dev Biol. 2023, 11: 1149499.
    [28] XUE Y Z, LI Z J, LIU W T, et al. Down-regulation of lncRNA MALAT1 alleviates vascular lesion and vascular remodeling of rats with hypertension [J]. Aging (Albany NY). 2019, 11(14): 5192-5205.
    [29] OMURA J, HABBOUT K, SHIMAUCHI T, et al. Identification of long noncoding RNA H19 as a new biomarker and therapeutic target in right ventricular failure in pulmonary arterial hypertension [J]. Circulation. 2020, 142(15): 1464-1484.
    [30] CAO L, ZHANG Z, LI Y, et al. LncRNA H19/miR-let-7 axis participates in the regulation of ox-LDL-induced endothelial cell injury via targeting periostin [J]. Int Immunopharmacol. 2019, 72: 496-503.
    [31] ZHAO H, SONG J, LI X, et al. The role of immune cells and inflammation in pulmonary hypertension: mechanisms and implications [J]. Front Immunol. 2024, 15: 1374506.
    [32] YANG X, QI F, WEI S, et al. The transcription factor C/EBPβ promotes HFL-1 cell migration, proliferation, and inflammation by activating lncRNA HAS2-AS1 in hypoxia [J]. Front Cell Dev Biol. 2021, 9: 651913.
    [33] CAI M, LI X, DONG H, et al. CCR7 and its related molecules may be potential biomarkers of pulmonary arterial hypertension [J]. Febs Open Bio. 2021, 11(6): 1565-1578.
    [34] JIANG Y, HEI B, HAO W, et al. Clinical value of lncRNA SOX2-OT in pulmonary arterial hypertension and its role in pulmonary artery smooth muscle cell proliferation, migration, apoptosis, and inflammatory [J]. Heart Lung. 2022, 55: 16-23.
    [35] [1] HUMBERT M, KOVACS G, HOEPER M M, et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension [J]. G Ital Cardiol, 2023, 24(4 Suppl 1): e1-e116.
    [36] [2] HOEPER M M, HUMBERT M, SOUZA R, et al. A global view of pulmonary hypertension [J]. Lancet Resp Med, 2016, 4(4): 306-322.
    [37] [3] DENG L, HAN X, WANG Z, et al. The landscape of noncoding RNA in pulmonary hypertension [J]. Biomolecules, 2022, 12(6): 796.
    [38] [4] 王利然, 杨丽红, 宁文华, 等. 长链非编码RNA调控血管新生的研究进展 [J]. 中国比较医学杂志, 2021, 31(04): 143-149.WANG L R, YANG L H, NING W H, et al. Research progress of long non-coding RNA involvement in angiogenesis [J]. Chin J Comp Med, 2021, 31(4): 143-149.
    [39] [5] 贡时雨, 范慧敏, 张旭敏, 等. LncRNA在心力衰竭预后判断和治疗中的潜力研究进展 [J]. 中国比较医学杂志, 2018, 28(02): 102-105.GONG S Y, FAN H M, ZHANG X M, et al. Research progress of lncRNA in prognosis and treatment of heart failure [J]. Chin J Comp Med, 2018, 28(02): 102-105.
    [40] [6] JIN Q, ZHAO Z, ZHAO Q, et al. Long noncoding RNAs: emerging roles in pulmonary hypertension [J]. Heart Fail Rev, 2020, 25(5): 795-815.
    [41] [7] WANG E, WANG H, CHAKRABARTI S. Endothelial-to-mesenchymal transition: an underappreciated mediator of diabetic complications [J]. Front Endocrinol (Lausanne), 2023, 14: 1050540.
    [42] [8] MONTEIRO J P, RODOR J, CAUDRILLIER A, et al. MIR503HG loss promotes endothelial-to-mesenchymal transition in vascular disease [J]. Circ Res, 2021, 128(8): 1173-1190.
    [43] [9] CAO T, JIANG Y, LI D, et al. H19/TET1 axis promotes TGF-β signaling linked to endothelial-to-mesenchymal transition [J]. Faseb J, 2020, 34(6): 8625-8640.
    [44] [10] THOMAS A A, BISWAS S, FENG B, et al. LncRNA H19 prevents endothelial-mesenchymal transition in diabetic retinopathy [J]. Diabetologia, 2019, 62(3): 517-530.
    [45] [11] LI H, ZHAO Q, CHANG L, et al. LncRNA MALAT1 modulates ox-LDL induced EndMT through the Wnt/β-catenin signaling pathway [J]. Lipids Health Dis, 2019, 18(1):62.
    [46] [12] QIN Y, ZHU B, LI L, et al. Overexpressed lncRNA AC068039.4 contributes to proliferation and cell cycle progression of pulmonary artery smooth muscle cells via sponging miR-26a-5p/TRPC6 in hypoxic pulmonary arterial hypertension [J]. Shock, 2021, 55(2): 244-255.
    [47] [13] HAO X, LI H, ZHANG P, et al. Down-regulation of lncRNA Gas5 promotes hypoxia-induced pulmonary arterial smooth muscle cell proliferation by regulating KCNK3 expression [J]. Eur J Pharmacol, 2020, 889: 173618.
    [48] [14] WANG D, XU H, WU B, et al. Long non?coding RNA MALAT1 sponges miR?124?3p.1/KLF5 to promote pulmonary vascular remodeling and cell cycle progression of pulmonary artery hypertension [J]. Int J Mol Med, 2019, 44(3): 871-884.
    [49] [15] WANG S, CAO W, GAO S, et al. TUG1 regulates pulmonary arterial smooth muscle cell proliferation in pulmonary arterial hypertension [J]. Can J Cardiol, 2019, 35(11): 1534-1545.
    相似文献
    引证文献
引用本文

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2024-07-02
  • 最后修改日期:2024-09-26
  • 录用日期:2024-10-22
您是第8978996 位访问者
版权所有:中国比较医学杂志 主管单位：中国科学技术协会 主办单位：中国实验动物学会 中国医学科学院医学实验动物研究所
地址：北京市朝阳区潘家园南里5号 邮 编 ：100021 电话：010-67779337 E-mail:bjb@cnilas.org
技术支持：北京勤云科技发展有限公司
防诈骗提示！请勿点击不明链接或添加个人微信。编辑部所有邮箱后缀均为@cnilas.org
关闭